MAPK8IP3 and non-small cell lung carcinoma: Our study also found that MAPK signaling pathway was closely related to osimertinib resistance of NSCLC, and RPS6KA1, CACNA1B and MAPK8IP3 were significantly enriched in “MAPK signaling pathway” (Table 3).